Sarcopenia and diffuse large B cell lymphoma

摘要

Diffuse large B-cell lymphoma is the most common hematological disorder. Immunochemotherapy based on R-CHOP provides a cure in 30 to 40 % of cases. Refractory or early relapsed patients have a very poor prognosis. The IPI score can help us to select the most serious patients; another adverse prognostic factor has recently been identified: sarcopenia. It is defined by a reduction in muscle mass and performance and is associated with a significant reduction in overall survival. Targeted treatment could change the prognosis of these patients.